EX-FILING FEES 4 fs42023a1ex-fee_nocturne.htm FILING FEE TABLE

Exhibit 107

 

Calculation of Filing Fee Tables

 

S-4

 

(Form Type)

 

Nocturne Acquisition Corporation

 

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered and Carry Forward Securities

 

  Security
Type		  Security
Class
Title		  Fee
Calculation
or Carry
Forward
Rule		  Amount
Registered		   Proposed
Maximum
Offering
Price Per
Unit		   Maximum
Aggregate
Offering
Price		   Fee Rate   Amount of
Registration
Fee(4)		   Carry
Forward
Form
Type		   Carry
Forward
File
Number		   Carry
Forward
Initial
effective
date		   Filing Fee
Previously
Paid In
Connection
with
Unsold
Securities
to be
Carried
Forward		 
Newly Registered Securities 
Fees to Be
Paid		  Equity  Common Stock, par value of
$0.0001 (1)(2)		  457(f)(2)   785,017    10.30   $8,085,675.10(3)  $0.000147600   $1,193.45                                         
Fees
Previously
Paid		  Equity  Common Stock, par value  of
$0.0001		  457(f)(2)   12,789,627    10.30   $131,733,159(3)  $0.00011020   $14,517                     
Carry Forward Securities 
Carry
Forward
Securities		                                                      
   Total Offering Amounts   $139,818,834.10        $15,710.45                     
   Total Fees Previously Paid             $14,517                     
   Total Fee Offsets                                    
   Net Fee Due             $1,193.45                     

 

(1)

 Pursuant to Rule 416(a), there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from share splits, share dividends or similar transactions.
   
(2) The number of shares of common stock of Nocturne Acquisition Corporation, par value $0.0001 per share (the “Nocturne Common Stock”), being registered includes up to 11,838,310 shares of Nocturne Common Stock estimated to be issued to Cognos Therapeutics, Inc.’s equity holders in connection with the business combination described herein, up to 1,150,000 shares of Nocturne Common Stock issuable in the aggregate to the holders of public rights to receive one-tenth of a share of Nocturne Common Stock, up to 46,500 shares of Nocturne Common Stock issuable in the aggregate to the holders of private rights to receive one-tenth of a share of Nocturne Common Stock, and up to 539,834 shares of Nocturne Common Stock issuable in connection with the conversion of certain of Nocturne’s related party advances and promissory notes.

 

(3) Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the Securities Act of 1933, as amended (the “Securities Act”). Cognos Therapeutics, Inc. (“Cognos”) is a private company, no market exists for its equity and it has an accumulated deficit. Therefore, the proposed maximum aggregate offering price is the stated value of the Cognos securities expected to be exchanged in the Merger.
   
(4) Determined in accordance with Section 6(b) of the Securities Act at a rate equal to $110.20 and $147.60, as applicable, per $1,000,000 of the proposed maximum aggregate offering price.